About Physiomics plc
Physiomics plc: Revolutionizing Oncology Drug Development
Physiomics is a renowned oncology drug development consultancy that has been at the forefront of cancer research for over two decades. The company uses its proprietary state-of-the-art Virtual Tumour™ technology and other cutting-edge tools to predict and better understand the effects of cancer treatments. Physiomics works with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.
The company's Virtual Tumour™ technology is a unique platform that simulates the behavior of tumors in response to different treatments. This allows researchers to test various drug combinations, dosages, and schedules in silico before conducting expensive animal or human trials. The platform also enables personalized medicine by modeling individual patient tumors based on their genetic profile, allowing for tailored treatment plans.
Physiomics' team comprises world-class scientists, oncologists, pharmacologists, bioinformaticians, and software engineers who work collaboratively to provide customized solutions for each client's specific needs. The company has a proven track record of delivering high-quality results within tight timelines while maintaining cost-effectiveness.
One of Physiomics' key strengths is its ability to integrate multiple data sources into its models. This includes genomic data from next-generation sequencing (NGS), transcriptomic data from microarrays or RNA sequencing (RNA-seq), proteomic data from mass spectrometry (MS), metabolomic data from nuclear magnetic resonance (NMR) spectroscopy or liquid chromatography-mass spectrometry (LC-MS), as well as clinical trial data such as pharmacokinetics (PK) and pharmacodynamics (PD).
The company's services cover all stages of drug development, including target identification/validation, lead optimization/selection, preclinical safety/toxicity testing, clinical trial design/optimization/monitoring/reporting, regulatory submission support/approval process management/post-marketing surveillance, and biomarker discovery/validation.
Physiomics has a strong track record of successful collaborations with pharmaceutical and biotech companies, academic institutions, and government agencies worldwide. Some of its notable clients include AstraZeneca, Merck KGaA, Pfizer, Roche, Sanofi-Aventis, Cancer Research UK, the European Union's Innovative Medicines Initiative (IMI), and the US National Cancer Institute (NCI).
The company's innovative approach to oncology drug development has been recognized by numerous awards and accolades. In 2019, Physiomics won the Queen's Award for Enterprise in Innovation for its Virtual Tumour™ technology. The company was also named as one of the top 50 most disruptive companies in Europe by Disrupt 100 in 2018.
In conclusion, Physiomics is a leading oncology drug development consultancy that leverages cutting-edge technology to predict and better understand the effects of cancer treatments. The company's Virtual Tumour™ platform enables personalized medicine while saving time and money during pre-clinical and clinical development. With a world-class team of experts and a proven track record of success, Physiomics is poised to revolutionize cancer research for years to come.